Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed), eta | Starlite/ChEMBL | No references |
Homo sapiens | RAB9A, member RAS oncogene family | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | ras-related protein Rab-5B | RAB9A, member RAS oncogene family | 201 aa | 165 aa | 30.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1904 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0038 | 0.577 | 0.4775 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0038 | 0.577 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Leishmania major | DNA polymerase eta, putative | 0.0054 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0054 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.0054 | 1 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1904 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.1904 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1904 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Echinococcus granulosus | dna polymerase eta | 0.0054 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0038 | 0.577 | 0.4775 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1904 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1904 | 0.1904 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1904 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1904 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1904 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0054 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1904 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.1904 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1904 | 0.1904 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1904 | 0.1904 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for Rab9 Promoter Activators. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 19.9526 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (binding) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase. (Class of assay: confirmatory) [Related pubchem assays: 1379 ] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.